Literature DB >> 14517075

Deletion of stem-loop 3 is compensated by second-site mutations within the Gag protein of human immunodeficiency virus type 1.

Liwei Rong1, Rodney S Russell, Jing Hu, Michael Laughrea, Mark A Wainberg, Chen Liang.   

Abstract

Encapsidation of human immunodeficiency virus type 1 (HIV-1) RNA involves specific interactions between viral Gag proteins and viral RNA elements located at the 5' untranslated region (UTR). These RNA elements are termed packaging (psi) or encapsidation (E) signals and mainly comprise the stem-loop 1 (SL1) and SL3 RNA structures. We have previously shown that deletion of the SL1 sequences is compensated by second-site mutations within Gag. Similar studies are now extended to SL3 and the results demonstrate that deletion of this RNA structure is rescued by two point mutations, i.e., A11V in p2 and I12V in nucleocapsid (NC). These two compensatory mutations are different from those associated with the rescue of SL1 deletion, suggesting that SL1 and SL3 may bind to different residues of Gag during viral RNA packaging. Analysis of virion-derived RNA in native agarose gels shows that deletion of SL3 leads to decreases in both viral RNA packaging and dimerization. These defects are corrected by the compensatory mutations A11V and I12V. Yet, defects in viral RNA dimerization at an early stage that were caused by the SL3 deletion in the context of a viral protease-negative mutation cannot be overcome by these two suppressor mutations. Therefore, the positive effects of A11V and I12V on dimerization of the SL3-deleted RNA must have taken place at the maturation stage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14517075     DOI: 10.1016/s0042-6822(03)00405-7

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Single point mutations in the zinc finger motifs of the human immunodeficiency virus type 1 nucleocapsid alter RNA binding specificities of the gag protein and enhance packaging and infectivity.

Authors:  Michal Mark-Danieli; Nihay Laham; Michal Kenan-Eichler; Asher Castiel; Daniel Melamed; Meytal Landau; Nicole M Bouvier; Matthew J Evans; Eran Bacharach
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 2.  Human Retrovirus Genomic RNA Packaging.

Authors:  Heather M Hanson; Nora A Willkomm; Huixin Yang; Louis M Mansky
Journal:  Viruses       Date:  2022-05-19       Impact factor: 5.818

3.  Transduction of human immunodeficiency virus type 1 vectors lacking encapsidation and dimerization signals.

Authors:  Nihay Laham-Karam; Eran Bacharach
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

4.  A riboswitch regulates RNA dimerization and packaging in human immunodeficiency virus type 1 virions.

Authors:  Marcel Ooms; Hendrik Huthoff; Rodney Russell; Chen Liang; Ben Berkhout
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 5.  Clinical significance of human immunodeficiency virus type 1 replication fitness.

Authors:  Carrie Dykes; Lisa M Demeter
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

Review 6.  Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably?

Authors:  Rodney S Russell; Chen Liang; Mark A Wainberg
Journal:  Retrovirology       Date:  2004-09-02       Impact factor: 4.602

Review 7.  NMR Studies of Retroviral Genome Packaging.

Authors:  Patricia S Boyd; Janae B Brown; Joshua D Brown; Jonathan Catazaro; Issac Chaudry; Pengfei Ding; Xinmei Dong; Jan Marchant; Colin T O'Hern; Karndeep Singh; Canessa Swanson; Michael F Summers; Saif Yasin
Journal:  Viruses       Date:  2020-09-30       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.